Clinical Trial Search

Primary: Number of Participants Free From Progression at 3 Years — 54 participants

Primary: Number of Patients With Treatment Related GI and/or GU Toxicity as Assessed by the NCI CTCTAE Version 4.0 — 1 Participants

Primary: Percentage of Patients Who Can Safely Tolerate and Complete Adjuvant Hormonal Therapy, Radiation Therapy and Docetaxel After a Radical Prostatectomy — 26 percentage of…

Primary: Number of Participants Who Completed the Maximum Time Allowed on Study Without Severe Acute Surgical Complications — 11 Participants

Primary: Pathologic Complete Response Was Assessed by Rigorous Pathological Examination by One of Two Pathologists — 0 participants

Primary: Freedom From Failure (FFF) — 7; 16; 5 Participants

Primary: Acute Grade 3 or Higher Treatment-related Toxicity Rate. — 1; 3 participants — p=<0.0001

Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants

Primary: Number of Participants With Biochemical Failure — 12; 52 Participants

Primary: Biochemical Disease-Free Survival (bDFS), Using Phoenix and ASTRO Definitions — 46; 27; 45; 27 Participants

Primary: Number of Participants With Progression-Free Survival — 66; 84 Participants — p=0.40

Primary: Proportion of Patients With Lymph Node Involvement — 4; 28 Participants

Primary: Number of Participants With Circulating Tumor Cells in the Peripheral Blood — 60; 5 Participants

Primary: Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy — .43 proportion of participants

Primary: Number of Participants With Biochemical Failure at 5 Years — 0; 30 Participants

Primary: Safety, as Measured by the Number of Patients With at Least One Adverse Event as Assess by NCI Common Terminology Criteria for Adverse Events (CTCAE) vs. 40 When…

Primary: Change in Patient Management — 6; 15; 21; 21 Participants

Primary: Pre-metastatic Niche Density — 75.6; 62.5 clusters/hpf — p=>0.05

Primary: Failure-free Survival — 75.5; 63.0 Percentage of participants

Primary: Late Grade ≥ 3 Gastrointestinal (GI) and Genitourinary (GU) Toxicity of Interest, Using the CTCAE v4.0 — 1; 0 Participants

Primary: Number of Patients Experiencing Dose-Limiting Toxicities — 1; 1; 0 Participants

Primary: To Evaluate the Clinical Efficacy of Enzalutamide — 31 months

Primary: Progression-free Survival (PFS) Assessment - Number of Participants With Disease Progression — 10; 14; 9; 8 participants

Primary: Percentage of Participants With Pathologic Complete Response (pCR) or Minimal Residual Disease (MRD) — 30; 16 percentage of participants — p=0.151

Primary: 10-Year Restricted Mean Survival Time for Overall Survival — 8.82; 9.11 years

Primary: Number of Participants With Any Grade 2 Toxicity Using Intensity Modulated Radiation Therapy (IMRT) to Treat the At-risk Lymph Nodes in Prostate Cancer ( up to First 10…

Primary: Maximum Tolerated Dose (MTD) — 40; 42.5 gray (Gy)

Primary: Median Tumor Volume Burden at Baseline Multi-parametric Magnetic Resonance Imaging (mpMRI) Before and After Surgery — 3.44; 0.62 cc

Primary: Number of Participants With Dose Limiting Toxicities (Phase I and Safety Run-In) — 0; 0 Participants

Primary: Change From Baseline in Tissue Gli1 Expression Levels Using qRT-PCR Analysis in Each Group (LDE225 and Observation) — 6; 0 Participants